Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review
Open Access
- 23 June 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (13) , 6981
Abstract
Immunohistochemistry remains an indispensable tool in diagnostic surgical pathology. In parathyroid tumours, it has four main applications: to detect (1) loss of parafibromin; (2) other manifestations of an aberrant immunophenotype hinting towards carcinoma; (3) histogenesis of a neck mass and (4) pathogenetic events, including features of tumour microenvironment and immune landscape. Parafibromin stain is mandatory to identify the new entity of parafibromin-deficient parathyroid neoplasm, defined in the WHO classification (2022). Loss of parafibromin indicates a greater probability of malignant course and should trigger the search for inherited or somatic CDC73 mutations. Aberrant immunophenotype is characterised by a set of markers that are lost (parafibromin), down-regulated (e.g., APC protein, p27 protein, calcium-sensing receptor) or up-regulated (e.g., proliferation activity by Ki-67 exceeding 5%) in parathyroid carcinoma compared to benign parathyroid disease. Aberrant immunophenotype is not the final proof of malignancy but should prompt the search for the definitive criteria for carcinoma. Histogenetic studies can be necessary for differential diagnosis between thyroid vs. parathyroid origin of cervical or intrathyroidal mass; detection of parathyroid hormone (PTH), chromogranin A, TTF-1, calcitonin or CD56 can be helpful. Finally, immunohistochemistry is useful in pathogenetic studies due to its ability to highlight both the presence and the tissue location of certain proteins. The main markers and challenges (technological variations, heterogeneity) are discussed here in the light of the current WHO classification (2022) of parathyroid tumours.Keywords
This publication has 185 references indexed in Scilit:
- Value of PAX 8 Immunostaining in Tumor DiagnosisAdvances in Anatomic Pathology, 2012
- Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumoursVirchows Archiv, 2011
- Morphological evaluation of parathyroid adenomas and immunohistochemical analysis of pcna and ki-67 proliferation markersTurkish Journal of Pathology, 2011
- Evidence for an early role for BMP4 signaling in thymus and parathyroid morphogenesisDevelopmental Biology, 2010
- Expansion of a Cell Population Expressing Stem Cell Markers in Parathyroid Glands From Patients With HyperparathyroidismAnnals of Surgery, 2010
- The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repressionNucleic Acids Research, 2009
- The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionMolecular Cancer, 2007
- Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinomaThe Journal of Pathology, 2003
- Ultrasound-Guided Fine Needle Aspiration Cytology of Parathyroid LesionsActa Cytologica, 2002
- Dendritic Cell Immunotherapy Induces Antitumour Response in Parathyroid Carcinoma and Neuroendocrine Pancreas CarcinomaHormone and Metabolic Research, 1999